# AstraZeneca: Phase 1 study closed enrollment, 226 enrolled (B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma |
| NCT ID | NCT04594642 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | B-cell Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Follicular Lymphoma |
| Intervention types | drug |
| Target enrollment | 226 |
| Site countries | United States, Australia, Japan, South Korea, Taiwan |
| Posted | 2020-10-20 |
| Planned start | 2021-03-02 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-25 |
| Last update posted | 2026-09-25 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 226 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04594642). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.